targeted alpha therapy tat emerging therapeutic modality thought best suited cancer micrometastases leukaemia lymphoma tat indicated solid tumours melanoma patients phase NUMBER clinical trial systemic targeted alpha therapy melanoma experienced marked regression subcutaneous internal tumours response ascribed killing cancer cells tumours targeted alpha therapy new observations support original hypothesis tumours regressed mechanism called tumour alpha therapy effect depends expression targeted receptors capillary pericytes contiguous cancer cells transfer alpha radiation anti vascular short range high energy